This book looks at "...the recent history and the many struggles related to advocacy for access to [antiretroviral] medicines of engaged civil society. Through the experiences of five middle-income countries - Brazil, China, Colombia, India, and Thailand." It presents "...the perspective of local civil society organisations about the national impact of intellectual property protection and access to medications. "These five countries were chosen due to their accumulated experience in this field, their capacity to produce generic medication, their activist efforts, and the exchange of ideas and information that already exists between them"
Documents MSF's experience of purchasing anti-retroviral drugs in ten low and middle income countries. The report looks at ARV selection, pricing and procurement issues. It highlights five issues: sources (quality), registration, prices, patents, and the continous availability of medicines
This annotated bibliography brings together references to scientific, legal and other materials on globalisation, patents and drugs. It is organised into sections on general articles (basic literature on the topic), country studies (by region), thematic sections on TRIPS (the World Trade Organization treaty on patents) and patents, drug research and development, and human rights and access to drugs. Finally a section on electronic information sources highlights useful websites and discussion groups on these issues. Each reference includes full bibliographic information and a thorough, descriptive abstract detailing the key points of each item
Since 1996, the Brazilian Ministry of Health has guaranteed free and universal access to antiretroviral treatment for people living with HIV/AIDS. Implementation of this policy has had political, financial, and logistical challenges. This article investigates the history and context of antiretroviral policy in Brazil, the logistics of the drugs distribution, and the government's strategies for acquisition of the drugs. Many antiretrovirals used in Brazil are produced domestically; the remainder, including some of the most expensive drugs, are purchased from abroad. Although the Brazilian policy of antiretroviral distribution has had notable success, it remains threatened by the high cost of acquisition of drugs, which has led to disputes with international pharmaceutical companies over prices and patents. Whether or not the Brazilian model of guaranteeing access to antiretroviral treatment for people living with HIV/AIDS can be applied in other countries or regions, much can be learned from the country's experience
Source e-bulletin on Disability and Inclusion